从血管活性因子角度研究抗纤灵方改善肾功能抑制肾纤维化的作用机制  

Mechanism of Kangxianling to improve renal function and inhibit of renal fibrosis from the view of vasoactive factors

作　　者：张长明[1] 周家俊[1] 何立群[2] 吴同茹[2] 彭文[3] 王云满[3] 王浩[3] 张先闻[4] 邓跃毅[4] 王怡[5] 

机构地区：[1]上海中医药大学附属市中医医院,上海200071 [2]上海中医药大学附属曙光医院,上海200021 [3]上海中医药大学附属普陀医院,上海200062 [4]上海中医药大学附属龙华医院,上海200032 [5]上海中医药大学附属岳阳医院,上海200437

出　　处：《中华中医药杂志》2014年第2期405-407,共3页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金(No.81173219);科技部中医药行业科研专项(No.201007005);高等学校博士学科点专项科研基金(No.20093107110006);上海市科委创新行动计划项目(No.11DZ1973100);上海高校创新团队建设项目(No.201203)~~

摘　　要：目的:通过对慢性肾脏病3期患者临床疗效及体内血管活性因子的影响,研究活血化瘀通络法能延缓慢性肾衰的进展的机制。方法:观察抗纤灵方对血管紧张素Ⅱ、Ⅰ型胶原、Ⅲ型胶原、血清纤维蛋白原,血及尿TGF-β1的影响,并与氯沙坦组相比较。结果:抗纤灵方组降低血清中Ⅰ型、Ⅲ型胶原水平,减少尿TGF-β1,与氯沙坦组比较差异有统计学意义(P<0.05);两组治疗后血管紧张素Ⅱ较治疗前均下降(P<0.01,P<0.05);血纤维蛋白原及血TGF-β1变化两者差异无统计学意义。结论:抗纤灵方可能通过抑制体内血管活性因子,减少胶原蛋白在肾脏的沉积,延缓肾衰的进展。Objective： To investigate the mechanism of Huoxue Huayu Tongluo therapy on delaying chronic renal failure through the clinical effect on CKD 3 patients and vasoactive factors in vivo. Methods： To investigate the influences of Kangxianling Decoction on angiotensin II, collagen type I, collagen type m, serum fibrinogen, blood and urinary TGF-β1, and compare with the control group （losartan）. Results： Kangqianling reduced type I, type m collagen levels in serum, reduced urinary TGF-β1. It had significant differences compared with losartan （P〈0.05）. The expression of Angiotensin 1I in two groups after treatment was decreased than before treatment （P〈0.05, P〈0.01）. Fibrinogen, blood TGF-β1 showed no significant changes of the two groups. Conclusion： Kangxianling granule can inhibit the vasoactive factors in vivo, reduce the collagen deposition in the kidney, and delay the progress of renal failure.

关 键 词：抗纤灵方 慢性肾脏病3期 活血化瘀 血管活性因子 

分 类 号：R277.5[医药卫生—中医学]